2023 World Conference on Lung Cancer (Posters)-EP06.03. Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma

EP06.03. Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma - PDF(Abstract)

Pdf Summary

This study conducted by researchers from Stanford University Medical Center aimed to compare the clinical impact of EGFR and KRAS mutations in patients with multifocal lung adenocarcinoma. The study included 241 subjects who underwent resection for either EGFR (n=150) or KRAS (n=91) lung adenocarcinoma between 2008 and 2022. <br /><br />The results showed that 70.7% of EGFR tumors and 30.8% of KRAS tumors were subsolid in nature. Additionally, 56% of EGFR tumors and 56% of KRAS tumors were found to be multifocal. The analysis revealed that patients with KRAS mutations had a higher prevalence of smoking history, larger dominant tumor size, higher stage, higher SUVmax, higher tumor mutation burden, and worse disease-free survival and overall survival compared to those with EGFR mutations. <br /><br />Furthermore, the study found that the survival without progression of secondary nodules (defined as increasing size or solid component or development of a new nodule) was significantly shorter for patients with KRAS mutations compared to EGFR mutations. Univariate analysis showed that dominant tumor size, tumor morphology, pStage, and KRAS mutations were significantly associated with secondary nodule progression free survival. However, multivariate analysis revealed that only KRAS mutation was independently associated with worse secondary nodule progression free survival. <br /><br />In conclusion, patients with KRAS mutations had a worse prognosis compared to those with EGFR mutations. It was also found that secondary nodules progress faster in patients with KRAS mutations, indicating a higher rate of eventual need for secondary nodule treatment in patients with KRAS multifocal disease.

Asset Subtitle

Jiahao Jiang

Meta Tag

Speaker Jiahao Jiang

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

Stanford University Medical Center

EGFR mutations

KRAS mutations

multifocal lung adenocarcinoma

clinical impact

resection

tumor morphology

smoking history

disease-free survival

overall survival